Craft

Ionis Pharmaceuticals

Stock Price

$39.7

2024-10-29

Market Capitalization

$6.3 B

2024-10-29

Revenue

$787.6 M

FY, 2023

Ionis Pharmaceuticals Summary

Company Summary

Overview
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The company offers SPINRAZA, a treatment for children and adults with spinal muscular atrophy (SMA); TEGSEDI, a medicine that treats polyneuropathy caused by hereditary transthyretin-mediated amyloidosis; and WAYLIVRA, a medicine used to treat familial chylomicronaemia syndrome (FCS).
Type
Public
Status
Active
Founded
1989
HQ
Carlsbad, CA, US | view all locations
Website
https://www.ionis.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Brett P. Monia

    Brett P. Monia, Chief Executive Officer, Director

  • C. Frank Bennett

    C. Frank Bennett, Executive Vice President, Chief Scientific Officer

  • Eric E. Swayze

    Eric E. Swayze, Executive Vice President, Research

  • Richard S. Geary

    Richard S. Geary, Executive Vice President, Chief Development Officer

Operating MetricsView all

Phase II Trials Products

13
7.1%

FY, 2023

Phase III Trials Products

9
28.6%

FY, 2023

Products Marketed

5
66.7%

FY, 2023

LocationsView all

1 location detected

  • Carlsbad, CA HQ

    United States

    2855 Gazelle Ct

Ionis Pharmaceuticals Financials

Summary Financials

Revenue (Q3, 2024)
$133.8M
Gross profit (Q3, 2024)
$132.7M
Net income (Q3, 2024)
($140.5M)
Cash (Q3, 2024)
$334.6M
EBIT (Q3, 2024)
($148.7M)
Enterprise value
$6.1B

Footer menu